SCHEMBL3449359

SCHEMBL3449359

O=S1(=O)CCN(CCNc2nc(Cl)ncc2Br)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
IRAK1 P51617 2/20 0.42
IRAK4 Q9NWZ3 1/20 0.39
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CXCR4 P61073 1/20 0.36
PGK1 P00558 4/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
SCN9A Q15858 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449796 0.93 CNR1 (0.39) CNR1CNR2IRAK1IRAK4TMEM97
SCHEMBL3448525 0.82 CXCR4 (0.50) CXCR4KMT2AMEN1CYP1A2CYP2C19
SCHEMBL13649046 0.79 PGK1 (0.47) PGK1
SCHEMBL3449182 0.77 STK17A (0.52) CNR1CNR2STK17BSTK17ATBK1
SCHEMBL3447060 0.75 MAPK1 (0.47) CXCR4KMT2ACYP2C19LMNATSHR
SCHEMBL20061673 0.72 IRAK1 (0.42) CNR1CNR2IRAK1IRAK4TMEM97
SCHEMBL3448511 0.71 STK17A (0.55) STK17BSTK17ATBK1
SCHEMBL3447092 0.70 KMT2A (0.50) KMT2AMEN1ABL1BCRSTK17B
SCHEMBL5151737 0.70 STK17A (0.50) KMT2AMEN1CYP1A2CYP2D6STK17B
SCHEMBL27635201 0.70 STK17B (0.44) KMT2AMEN1ABL1BCRSTK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CNR1 653/4885CNR2 517/4885IRAK1 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.